Flagship · Bulletin

Macro rationale

Live inputs say calm-but-crowded, not deteriorating. Volatility and credit are benign: VIX 16.5 (−11.3% vs 200d), HY OAS 2.73% below its SMA, 2s10s +0.38 un-inverted. Nothing in the flow set has broken: hyperscaler 2026 capex ~$725B intact with Alphabet/Amazon guides reaffirmed Aug 4; HBM sold out across the three-supplier oligopoly with TSMC CoWoS booked through 2026 (180-190k wafers overflowing to Amkor); term U3O8 $94-95.50/lb vs a $60+/lb contract book; copper at all-time highs into a ~320kt 2026 deficit; FY2026 defense enacted at $839.2B (P.L. 119-75). What HAS changed is positioning, not fundamentals: QQQ sits +10.91% above its 200d and the §2 AI-load look-through auto-fired at 33.32% (entry-weight basis 35.01%), above its 30% early-warning trigger and at the 35% hard cap. That is a mechanical concentration breach, and it is the whole reason this run exists. The macro digest scores compute −3 (trim signal), energy +5 and defense +2 on the persistent Hormuz disruption (44 vessels redirected). Cash band is NEUTRAL base 5-15% with an escalated ceiling of 30% (extension + concentration active); I am targeting 14.00%, essentially unchanged from last run's 14.25% working reserve — the cure is expressed as trims recycled into non-AI diversifiers, not as a cash raise, because no escalator signal has newly fired and the regime read is unchanged from July 27. stale_policy=YES is noted; the only reason two names appear as opens is the 18-position schema floor (the book has shrunk to 16 after the PSN close and MP's sub-1% dust close), and both are pre-vetted watchlist names scoring ≥60 that I journaled as deferred displacement candidates on July 29.

Thesis

Scope-locked, event-driven concentration cure. The §2 AI-load look-through fired over its 30% trigger, so the mandate is a trim toward diversification — not a flow break. Two tickets, both inside the scoped list, both on the weakest-scored AI-correlated energy names rather than on the compute franchises (which are already sized at 2.6-5.8% and mostly improving). (1) CCJ −3.75pp to 3.30%: the position briefer prints a score crash 67→45 and an out_of_investable classification while the paper book still shows 67 — an unresolved conflict I will not size 7% into. The uranium funder (term U3O8 $94+, DOE $17.5B AP1000 commitment, Trump-Saudi deal) is intact, so this is a right-size, not an exit, and NEM+SCCO still carry the §5.3 hedge floor. (2) GEV −2.00pp to 2.92%: wind revenue −10% and orders −40% in Q2, score 61 sitting one leg above the floor; the $176B backlog and turbines-sold-out-through-2030 gas thesis is unbroken, so again a right-size. Together these take entry-weight AI-load from 35.01% to 29.26%, back under the trigger. Everything else is re-affirmed verbatim at prior entry weight, delta 0 — including the three locked fresh names (VRTX, ARGX, LUNR) and the two large defense holdings. Proceeds fund GD and VEEV at the 3% minimum: both are non-AI diversifiers I explicitly journaled as deferred on July 29, and both are needed to satisfy the 18-position schema floor after PSN and MP left the book. Mid-cap sleeve: DRS, LMT and ORCL were reviewed; none exceeds an incumbent by

Reflection

Concentration escalator, not a flow break: AI-load 35.01% entry-basis at its hard cap. Every named funder — capex, U3O8 $94+, copper ATH, $839B defense — is intact.

Two things nag. First, the book has quietly shrunk to 16 names — PSN closed, MP dust-closed — and the 18-position schema floor now FORCES opens under stale_policy. Last month the same mechanic forced me to CARRY a broken PSN; this week it forces me to BUY. The position-count floor is not a neutral guardrail in either direction. Second, CCJ prints score 45 (broken, out_of_investable) in the briefer and 67 in the paper book simultaneously. I sized down rather than resolve it by guess — but I have now learned twice that unresolved score conflicts on a 7% weight are the expensive kind of ambiguity

Positions (16)

• MUMicron Technologycompute

  hold3.36%86
  flow acceleratingconf

  Funder

  Only US-domiciled leading-edge DRAM/HBM maker: 84.6% gross margin, FCF positive, and genuine supply discipline after two decades of cycle abuse. Named flow: 16 multi-year Strategic Customer Agreements worth ~$100B contracted; HBM3E/HBM4 production entirely sold out across the three-supplier oligopoly through 2026; ~$725B 2026 hyperscaler capex; BofA reiterated Buy with a $1,550 PT (Aug 4) arguing

  Unwind

  DRAM/NAND spot collapse or HBM oversupply breaking the shortage thesis; hyperscaler capex cut; erosion of the 16-SCA contract book; CXMT Beijing capacity landing at scale and breaking pricing power.

  Catalyst

  Next quarterly print with HBM revenue mix disclosure; 2027 HBM4 capacity allocation announcements.

  Scenarios · 12mo targets

  $1,350.00 base

  $1,650.00 bull — HBM4 allocations reprice higher and the SCA book converts at premium ASPs; memory stays sold out through 2027 as CXMT capacity slips.

  $850.00 bear — CXMT Beijing fab lands at scale, DRAM spot rolls over, and hyperscalers pause HBM orders into a 2027 capex digestion year.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold5.07%86
  flow steadyconf

  Funder

  World-leading foundry with an effective monopoly at <=3nm — every meaningful AI accelerator routes through it. >50% GM, prodigious FCF, famously disciplined capex, ~73% foundry share. Named flow: Alphabet and Amazon capex guides reaffirmed expansionary (Aug 4); CoWoS booked out through 2026 with 180-190k wafers/yr formally outsourced to Amkor; CHIPS $6.6B Arizona disbursement; 2027 price hikes ann

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event Arizona capacity cannot offset; hyperscaler capex guides cut in aggregate.

  Catalyst

  Q3 monthly revenue prints and the next capex guide; CoWoS capacity milestone of 130k WPM by Q4 2026.

  Scenarios · 12mo targets

  $500.00 base

  $600.00 bull — 2027 price hikes stick, CoWoS expansion clears backlog, and N2 ramps with Apple+NVIDIA both committed at high volume.

  $340.00 bear — AI capex digestion in 2027 cuts leading-edge utilization; SMH-style multiple compression takes the ADR back toward 15x.

• NVDANVIDIAcompute

  hold3.14%72
  flow softeningconf

  Funder

  AI-accelerator franchise with the CUDA software moat — ~74.9% gross margin, fortress balance sheet, developer lock-in no ASIC rival has replicated. Named flow: ~$725B 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT ~$190B, AMZN ~$200B, GOOGL $180-190B, META $125-145B) plus the Stargate JV. Softening on the margin: $3.4B of AI-complex insider selling with zero purchases, AWS custom silicon

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; hyperscaler in-sourcing and AMD wins pushing competitor share toward the 25% TAM invalidation line; a compute export-control tightening that removes a material revenue block.

  Catalyst

  Next data-center revenue print and Rubin ramp commentary; AWS/Google custom-silicon share disclosures.

  Scenarios · 12mo targets

  $300.00 base

  $380.00 bull — Rubin ramps into an undiminished capex line and inference share holds above 70%, re-rating the multiple on accelerating datacenter revenue.

  $180.00 bear — ASIC in-sourcing at AWS/Google plus a 2027 capex deceleration takes datacenter growth under 20% and compresses a 50x multiple.

• ASMLASML Holdingcompute

  hold2.57%62
  flow softeningconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, no commercial-scale alternative at 2nm, multi-year backlog, ~50% gross margin. Named flow: Intel's July 2026 Ultra 3 design win confirms High-NA moves to volume deployment; Norway GPFG holds and Coatue/Third Point added in Q1; the TSMC/Samsung/Intel 2025-27 EUV orderbook backstops cash flow.

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening removing a material share of the orderbook; a credible non-EUV patterning path at 2nm; Chinese DUV competition taking measurable installed-base share.

  Catalyst

  Next quarterly bookings print — the single number that resolves the -23pt score drift.

  Scenarios · 12mo targets

  $1,900.00 base

  $2,300.00 bull — High-NA bookings inflect on Intel and TSMC 2nm commitments; the July sentiment drawdown reverses as the orderbook is reconfirmed.

  $1,250.00 bear — Chinese DUV substitution plus an AI-capex scare take book-to-bill below 0.7 and de-rate a 37x forward multiple.

• AVGOBroadcomcompute

  hold2.54%63
  flow softeningconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software moat — huge FCF, $7B+ annual buyback, serial dividend grower, one of the best capital-allocation records in semis under Hock Tan. Named flow: Google TPU multi-generation program, Meta MTIA, and the Anthropic 3.5GW ASIC contract; $30B+ AI bookings disclosed.

  Unwind

  AI custom-chip revenue stalling below a $25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise; VMware renewal churn breaking the software annuity.

  Catalyst

  Next quarterly AI-semiconductor revenue disclosure and VMware renewal-rate commentary.

  Scenarios · 12mo targets

  $480.00 base

  $580.00 bull — Anthropic and Google TPU programs push AI revenue well past a $25B run-rate while VMware renewals confirm the software annuity.

  $300.00 bear — Hyperscalers pull ASIC design in-house, AI bookings stall under $25B, and the SMH de-rating takes the multiple with it.

• ANETArista Networkscompute

  hold2.26%67
  flow acceleratingconf

  Funder

  Durable hyperscaler-networking franchise and consistent share-gainer since 2004 — ~61.9% gross margin, net cash, no debt, and the single-image EOS software moat that keeps switching costs high under Jayshree Ullal. Named flow: Q2 delivered the first $3B quarter ($3.036B, +37.7% YoY) with FY26 guidance raised to ~$12.6B (~40% growth); Microsoft and Meta remain the named funding customers; a new hyp

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a named hyperscaler footprint; gross margin breaking below the high-50s.

  Catalyst

  Next quarter's gross-margin line and hyperscaler customer-concentration disclosure.

  Scenarios · 12mo targets

  $225.00 base

  $280.00 bull — 1.6T AI fabric wins broaden the customer base beyond Microsoft/Meta and FY26 lands above the raised ~$12.6B guide.

  $135.00 bear — Gross margin erodes on AI-mix dilution while 42% two-customer concentration bites in a capex pause; 48x forward multiple compresses.

• CCJCamecoenergy

  trim4.06%-3.75pp45
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): tier-1 Saskatchewan uranium franchise (McArthur River/Cigar Lake) plus the 49% Westinghouse JV with Brookfield — irreplaceable permitted low-cost tonnes in a stable jurisdiction. Named flow: term U3O8 $94-95.50/lb vs a legacy contract book at $60+/lb; DOE $17.5B AP1000 loan commitment; Kazatomprom's 8Mlb output cut sustaining the structural deficit; the Trump-Saudi civ

  Unwind

  Uranium spot/term price collapse; contract-book erosion or failure to reprice legacy contracts upward; a reactor-build program cancellation; confirmation that the score-45 out_of_investable classification reflects a real fundamental break rather than a data conflict.

  Catalyst

  Next quarterly contract-book repricing disclosure; resolution of the score 45-vs-67 conflict at the next full review.

  Scenarios · 12mo targets

  $90.00 base

  $115.00 bull — Legacy contracts reprice toward the $94+ term market and Westinghouse AP1000 orders convert on the DOE loan commitment.

  $55.00 bear — Term uranium rolls over as Kazatomprom restores output; the score-45 classification proves to be a genuine fundamental break.

• GEVGE Vernovaenergy

  trim3.59%-2.00pp61
  flow steadyconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — record ~$176B backlog, turbines sold out through 2030, 10-20% price realization on new orders, quadrupled FCF, and a three-player global oligopoly. Named flow: Q2 orders +88% and revenue +22%; Norway GPFG added post-spin; Oracle/Alphabet datacenter capex pull-through; DOE Gen III+ Tier-1 $800M award with TVA for BWRX-300 at Clinch River.

  Unwind

  Gas-turbine backlog cancellation or a hyperscaler power-capex cut; wind losses widening enough to consume gas-segment profit; EV/EBITDA breaching the ~25x exit threshold with orders decelerating.

  Catalyst

  Next backlog disclosure and wind-segment restructuring update; Clinch River BWRX-300 construction milestones.

  Scenarios · 12mo targets

  $820.00 base

  $1,000.00 bull — Wind is ring-fenced or exited, gas backlog converts at 10-20% price realization, and SMR awards add a second growth leg.

  $500.00 bear — Wind losses widen from the -10% revenue/-40% orders base and consume gas profit; a hyperscaler power-capex pause stalls the backlog.

• SCCOSouthern Copperenergy

  hold9.85%67
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, 59.8% gross margin, FCF positive and a large dividend; Grupo Mexico control enforces capital discipline. Named flow: copper at all-time highs above $6.50/lb against a ~320kt 2026 supply deficit; BHP's copper profit surpassing iron ore validating the structural shift; AI/datacenter demand projec

  Unwind

  Copper price collapse breaking the deficit thesis; Tia Maria / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress.

  Catalyst

  Next quarterly production and cash-cost report; Tia Maria construction milestones.

  Scenarios · 12mo targets

  $205.00 base

  $250.00 bull — The 2026 deficit widens as grid and datacenter demand compounds; Tia Maria adds volume into an ATH price deck.

  $140.00 bear — A China-led demand air pocket collapses copper; Peruvian permitting reverses and the dividend is cut.

• NEMNewmont Corporationenergy

  hold9.25%84
  flow steadyconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: sustained central-bank gold accumulation as reserve diversification; TD Cowen upgraded to Buy (July 14) on valuation with a $127 PT citing gold's structural strength; the hedge earns its slot again

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; a peer-lagging production miss.

  Catalyst

  Next quarterly AISC print — the number that confirms or breaks the cost-discipline thesis.

  Scenarios · 12mo targets

  $135.00 base

  $170.00 bull — Central-bank buying continues while a Fed pivot compresses real rates; AISC discipline holds and FCF funds a larger return of capital.

  $90.00 bear — Durable disinflation plus a real-rate surge kills the safe-haven bid; cost overruns at tier-1 assets break the FCF story.

• KTOSKratos Defensedefense

  hold11.94%62
  flow steadyconf

  Funder

  Tactical drones (XQ-58A Valkyrie), hypersonics and turbine engines — a scarce non-prime supplier of attritable airframes with 24.2% gross margin. Named flow intact: DoD MACH-TB 2.0 IDIQ prime ($1.45B ceiling), Project Helios $68.3M single-award hypersonic materials center, USMC Valkyrie MUX mods, the Pentagon 'Drone Dominance' program (22k+ units), and a $49M NSWC Oriole solid-rocket-motor award i

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp with FCF staying negative; a DoD unmanned-systems funding cut, or FY2027 appropriations slipping past October 1 into a repeat-CR that halts new starts.

  Catalyst

  FY2027 appropriations progress ahead of the October 1 deadline; next quarterly FCF and drone-segment margin print.

  Scenarios · 12mo targets

  $70.00 base

  $95.00 bull — Drone-dominance volume converts MACH-TB and Valkyrie awards into scale revenue and FCF turns positive on operating leverage.

  $38.00 bear — FCF stays negative through the ramp and an FY2027 CR freezes new starts, stalling the unmanned-systems procurement wave.

• HEIHEICOdefense

  hold11.07%68
  flow acceleratingconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF at 20%+ with a disciplined serial-acquisition model (~$1B/yr) and PMA parts that are structurally cheaper than OEM. Named flow: record Q2 with net income +49% YoY, ETG operating income +56%, FSG and ETG both above consensus; NDAA mandatory funding plus the

  Unwind

  Organic growth decelerating below 6% WITH margin compression; forward P/E sustained above 50x with growth deceleration confirmed (valuation alone is not the trigger); a value-destroying large acquisition breaking the capital-allocation record.

  Catalyst

  Next quarterly organic-growth split (FSG vs ETG) — the number that tests the 54x forward multiple.

  Scenarios · 12mo targets

  $430.00 base

  $510.00 bull — MRO cycle and ETG acquisitions keep organic growth in the teens; the family compounding machine sustains a premium multiple.

  $290.00 bear — Organic growth decelerates below 6% while a 54x forward multiple de-rates — the confirmed invalidation combination.

• LLYEli Lillybiology

  hold6.09%73
  flow acceleratingconf

  Funder

  Premier pharma compounder — the Mounjaro/Zepbound GLP-1 franchise (~60% US share) plus oral orforglipron (Foundayo, FDA-approved) and retatrutide in Phase 3, on 82.9% gross margin with strong FCF. Named flow: Q2 blew out with Mounjaro +91% and Zepbound +44% revenue growth; a $27B US manufacturing expansion that also positions the franchise favourably against the July 31 Section 232 pharma tariff;

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing on safety or durability; IRA/MFP negotiation reaching the GLP-1 franchise in an IPAY 2028 selection.

  Catalyst

  Retatrutide Phase 3 full readout; IPAY 2028 Part B/Part D selection list under IRA negotiation.

  Scenarios · 12mo targets

  $1,250.00 base

  $1,500.00 bull — Retatrutide confirms 28%+ weight loss and orforglipron scales orally; the franchise extends toward the $2T market-cap case.

  $800.00 bear — Script share slips >5pts to Novo, retatrutide disappoints, and IRA negotiation reaches incretins — 40x forward compresses hard.

• VRTXVertex Pharmaceuticalsbiology

  hold4.07%79
  flow steadyconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine with 86.8% gross margin, no meaningful competition, and a fortress net-cash balance sheet. Named flow: the $10B Crinetics acquisition (Jul 30) funds a second commercial leg beyond CF; Casgevy commercializing across 12+ jurisdictions under the Medicare Cell & Gene Therapy Access Model; suzetri

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value or pushing forward P/E toward the 30x invalidation line; a suzetrigine launch failure in non-opioid pain.

  Catalyst

  Suzetrigine launch metrics and the first Crinetics accretion disclosure. Conviction lock runs to 2026-08-09.

  Scenarios · 12mo targets

  $560.00 base

  $660.00 bull — Suzetrigine scales in non-opioid pain and Crinetics adds an endocrine leg, breaking the single-franchise discount on the CF monopoly.

  $390.00 bear — CF erodes to next-gen competition faster than non-CF replaces it and the $10B Crinetics deal proves value-destructive.

• ARGXargenxbiology

  hold3.79%70
  flow acceleratingconf

  Funder

  argenx — the Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: a first-mover platform with a decade of indication runway, self-funded, commercial-stage, high-margin and net cash. Named flow: FDA expanded the gMG label to all serotypes including seronegative (~18% TAM expansion); Sanofi's rival riliprubart failed Phase 3 in CIDP, removing the most credible competitor; the June R&D w

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant taking measurable share.

  Catalyst

  Myositis and Sjogren's registrational readouts; next quarterly Vyvgart revenue print. Conviction lock runs to 2026-08-10.

  Scenarios · 12mo targets

  $1,000.00 base

  $1,200.00 bull — Myositis and Sjogren's expand the label into a multi-indication FcRn franchise while Sanofi's CIDP failure leaves the field open.

  $680.00 bear — Vyvgart growth plateaus in gMG/CIDP and a pipeline indication misses, collapsing the platform premium.

• LUNRcompute

  hold1.10%55
  flow steadyconf

  Funder

  Intuitive Machines — named government backlog is the whole thesis: NASA Near Space Network IDIQ ($4.82B ceiling, active), a $148.3M firm-fixed-price CLPS task order, the Space Force Andromeda IDIQ ($6.2B ceiling), $428.9M of new Q1 2026 contracts from SDA and NASA, and record ~$1.1B contracted backlog. NASA's fresh $600M lunar contract round directly extends the CLPS pipeline.

  Unwind

  Backlog conversion stalling; the profitability pathway breaking; a NASA CLPS or SDA program funding cut; further insider selling on top of the CTO's $3.3M June sale. Resolve at the first non-stale full review — score 54 is below the investable floor.

  Catalyst

  Next backlog-conversion and cash-burn disclosure; NASA CLPS task-order awards from the $600M round. Conviction lock runs to 2026-08-19.

  Scenarios · 12mo targets

  $12.00 base

  $18.00 bull — Backlog converts to revenue on schedule, the $1B 2026 guide is met, and NASA's $600M round adds firm task orders.

  $4.00 bear — Backlog conversion stalls, cash burn forces dilution, and a CLPS/SDA funding cut removes the only named funder.

Warnings

• stale_policy guard: GD open → hold (delta zeroed)
• stale_policy guard: VEEV open → hold (delta zeroed)
• cash_band: final cash 16.25% above neutral base band top 15% (escalator active: extension, concentration; §3b dry-powder headroom +17.5pp (unfilled opportunistic sleeve → cash)) (§5.4)
• cash_reconcile: executed cash 23.44% sits 9.19pp ABOVE the intent baseline — committed weights re-anchored 2.11pp down toward live across KTOS (§5.4 commit honesty; no mechanical buys — redeployment stays an Opus decision)
• live_sizing: 1 ticket(s) re-expressed against the executed ledger (§6.6)

Conviction-lock actions

No conviction-lock refusals or overrides this run.

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.